Earnings Releases

Pulmatrix, Inc. reported the year ended December 31, 2023 results: revenue $7.3 million.

“Revenues increased $1.2 million to $7.3 million for the year ended December 31, 2023, compared to $6.1 million for the year ended December 31, 2022.”

Galera Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.

“Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates”

Pacific Coast Oil Trust reported January 2024 results: revenue approximately $3.2 million, net income net profits were approximately $1.1 million.

“calculation for the Developed Properties reflected operating income of approximately $1.3 million, as revenues from the Developed Properties were approximately $3.2 million, lease operating expenses including property taxes were approximately $1.9 million, and development costs (including adjustments from prior periods) were approximately $30,000.”

CalciMedica, Inc. reported the year ended December 31, 2023 results: net income $34.4 million, or $7.66 per share (basic and diluted), EPS $7.66 per share (basic and diluted).

“Net loss was $34.4 million, or $7.66 per share (basic and diluted) for the year ended December 31, 2023.”

CV Sciences, Inc. reported the fourth quarter of 2023 results: revenue $3.8 million.

“Revenue of $3.8 million for the fourth quarter 2023 compared to $4.1 million in the third quarter 2023;”

CV Sciences, Inc. reported fiscal year ended December 31, 2023 results: revenue $16.0 million.

“Generated revenue of $16.0 million for fiscal 2023 compared to $16.2 million for 2022;”

Cepton, Inc. reported financial results for fourth quarter and fiscal year ended December 31, 2023.

“On March 28, 2024 , Cepton, Inc., a Delaware corporation (the “ Company ”), announced financial results for its fourth quarter and fiscal year ended December 31, 2023.”

Nutex Health Inc. reported financial results for the year ended December 31, 2023.

“On March 28, 2024, Nutex Health Inc. (the “Company”) announced its financial and operating results for the quarter ending December 31, 2023. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.”

Nutex Health Inc. reported financial results for the quarter ending December 31, 2023.

“On March 28, 2024, Nutex Health Inc. (the “Company”) announced its financial and operating results for the quarter ending December 31, 2023. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.”

Immunome Inc. reported the full-year ended December 31, 2023 results: net income $106.8 million, EPS $5.38.

“Immunome reported a net loss of $106.8 million, or basic and diluted net loss per share attributable to common stockholders of $5.38, for the year ended December 31, 2023.”

Arcadia Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.

“On March 28, 2024 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the fourth quarter and year ended December 31, 2023.”

Kodiak Sciences Inc. reported financial results for the quarter and year ended December 31, 2023.

“On March 28, 2024, Kodiak Sciences Inc. (the “Company”) published a press release reporting the Company’s financial results for the quarter and year ended December 31, 2023 and business highlights.”

ZEVRA THERAPEUTICS, INC. reported fourth quarter and fiscal year ended December 31, 2023 results: revenue $13.2M.

“Corporate Updates Launch of OLPRUVA ® underway Topline results from KP1077 phase 2 study demonstrate clinically meaningful benefits for key IH symptoms Q4 2023 net revenue of $13.2M, and FY 2023 net revenue of $27.5M Conference call scheduled for today, March 28, 2024, at 4:30 p.m. ET Celebration, FL – March 28, 2024 – Zevra Therapeutics, Inc. (NasdaqGS:”

Axe Compute Inc. reported the year ended December 31, 2023 results: revenue approximately $1.8 million, net income approximately $14 million, EPS $3.48 per share.

“results for the year ended December 31, 2023, and provided a corporate update. The company reported a net loss of approximately $14 million on total revenue of approximately $1.8 million for the year ended December 31, 2023. Q4 2023 and Recent Highlights: Reported meaningful progress with FluGen collaboration designed to bring a first-of-its-kind intranasal flu”

Fortress Biotech, Inc. reported the full year ended December 31, 2023 results: revenue Record consolidated net revenue of $84.5 million.

“Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights Record consolidated net revenue of $84.5 million for full-year 2023”

ASSEMBLY BIOSCIENCES, INC. reported the quarter and year ended December 31, 2023 results: revenue $7.2 million, net income $61.2 million, EPS $13.38 per basic and diluted share.

“as of the year ended December 31, 2022. The company’s cash position is projected to fund operations into the second half of 2025. • Revenues from collaborative research were $7.2 million for the year ended December 31, 2023. There was no revenue recognized for the same period in 2022. Revenue for the year ended December 31, 2023, consists of $4.4 million”

Cocrystal Pharma, Inc. reported financial results for the 12 months ended December 31, 2023.

“Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) reports financial results for the 12 months ended December 31, 2023, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.”

Data Storage Corp reported year ended December 31, 2023 results: revenue $25.0 million.

“Data Storage Corporation Reports Record Revenue of $25 Million and Achieves Profitability for the 2023 Fiscal Year”

Eledon Pharmaceuticals, Inc. reported the year ended December 31, 2023 results: net income net loss of $40.3 million, or $1.64 per share, EPS $1.64 per share.

“The Company reported a net loss of $40.3 million, or $1.64 per share, for the year ended December 31, 2023, compared to a net loss of $88.0 million, or $6.16 per share, in 2022.”

Eledon Pharmaceuticals, Inc. reported the three months ended December 31, 2023 results: net income net loss of $9.6 million, or $0.32 per share, EPS $0.32 per share.

“The Company reported a net loss of $9.6 million, or $0.32 per share, for the three months ended December 31, 2023, compared to a net loss of $58.4 million, or $4.09 per share, for the same period in 2022.”

Dare Bioscience, Inc. reported financial results for the fiscal year ended December 31, 2023.

“On March 28, 2024, Daré Bioscience, Inc. (the “Company”), issued a press release announcing its financial results for the fiscal year ended December 31, 2023”

SELLAS Life Sciences Group, Inc. reported financial results for the year ended December 31, 2023.

“On March 28, 2024, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the year ended December 31, 2023 and providing a corporate update.”

IT TECH PACKAGING, INC. reported financial results for the fourth quarter and audited financial results for the fiscal year ended December 31, 2023.

“issued a press release announcing its unaudited financial results for the fourth quarter and audited financial results for the fiscal year ending December 31, 2023”

22nd Century Group, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $7.4 million, net income $22.1 million or $0.66 per share, EPS $0.66 per share.

“on recent business highlights. ​ Fourth quarter results and recent business activities included: ● Net revenue from continuing operations in the fourth quarter of 2023 was $7.4 million, ● Exited hemp/cannabis operations to fully focus on tobacco harm reduction and contract manufacturing activities, ● Substantially reduced operating costs through efficiency”

FEMASYS INC reported year ended December 31, 2022 results: net income net loss of $11,394,170, or $0.96 per basic and diluted share attributable to common stockholders.

“Net loss was $14,247,124 or $0.93 per basic and diluted share attributable to common stockholders, for the year ended December 31, 2023, compared to net loss of $11,394,170, or $0.96 per basic and diluted share attributable to common stockholders, for the year ended December 31, 2022”

FEMASYS INC reported year ended December 31, 2023 results: net income Net loss was $14,247,124 or $0.93 per basic and diluted share attributable to common stockholders.

“Net loss was $14,247,124 or $0.93 per basic and diluted share attributable to common stockholders, for the year ended December 31, 2023, compared to net loss of $11,394,170, or $0.96 per basic and diluted share attributable to common stockholders, for the year ended December 31, 2022”

TSS, Inc. reported financial results for the three and twelve months ended December 31, 2023.

“On Thursday, March 28, 2024, TSS, Inc. (the “Company”), issued a press release reporting certain financial results of the Company for the three and twelve months ended December 31, 2023.”

Galaxy Gaming, Inc. reported fiscal year 2024 results: revenue $29.0 - $30.0. Guidance initiated.

“Actual 2024 Range Midpoint Change Recurring License Revenue $ 28.0 $34.0 - $35.0 23.2% Sale of Perpetual Licenses 3.7 1.0 - 1.5 (66.2)% Gross Revenue $ 31.7 $35.0 - $36.5 12.8% Royalties Netted against Gross Revenue (3.9) (6.0 - 6.5) 60.3% Net Revenue $ 27.8 $29.0 - $30.0 6.1% Adjusted EBITDA $ 10.6 $12.0 - $13.0 17.9% In the Disaggregation of Revenue table in Exhibit 1, Recurring License Revenue in GG Digital for Q4 2022 was incorrect.”

Galaxy Gaming, Inc. reported the year ended December 31, 2023 results: revenue $27,789K, net income $(1,808)K.

“Fiscal Year 2022 • Revenue (gross) increased 23% to $31,729K • Revenue (net) increased 19% to $27,789K • Net loss of $(1,808)K vs. net loss of $(1,773)K • Adjusted EBITDA increased 1% to $10,635K o Increased 7% when adjusting FY 22 for ERTC Balance Sheet Changes (vs.”

Galaxy Gaming, Inc. reported the quarter ended December 31, 2023 results: revenue $6,737K, net income $(820)K.

“Q4 2022 • Revenue (gross) increased 25% to $8,382K • Revenue (net) increased 13% to $6,737K • Net loss of $(820)K vs. net income of $55K • Adjusted EBITDA decreased 10% to $2,828K o Increased 10% when adjusting Q4 22 for ERTC • Fiscal Year 2023 vs.”

AGILE THERAPEUTICS INC reported the three months and fiscal year ended December 31, 2023 results: revenue Net revenue for the fourth quarter 2023 was $3.6 million.

“On March 28, 2024, Agile Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months and fiscal year ended December 31, 2023 and an update on the Company’s operations.”

SCYNEXIS INC reported the year ended December 31, 2023 results: net income $67.0 million, EPS $1.40 basic income per share.

“Net income for the full year 2023, was $67.0 million, or $1.40 basic income per share”

REED'S, INC. updated its full year 2024 guidance (initiated).

“FY 2024 Financial Outlook The Company projects net sales growth, gross margin expansion, and to achieve modified EBITDA profitability for the full year 2024.”

REED'S, INC. reported twelve months ended December 31, 2023 results: revenue $44.7 million.

“FY 2023 Financial Highlights (vs. FY 2022): ● Net sales were $44.7 million compared to $53.0 million.”

REED'S, INC. reported three months ended December 31, 2023 results: revenue $11.7 million.

“Q4 2023 Financial Highlights (vs. Q4 2022): ● Net sales were $11.7 million compared to $15.0 million.”

CHINA AUTOMOTIVE SYSTEMS INC/2 reported the fiscal year ended December 31, 2023 results: revenue $576.4 million, EPS $1.25.

“Net sales increased by 8.8% to an annual record of $576.4 million compared to $529.6 million in 2022”

CHINA AUTOMOTIVE SYSTEMS INC/2 reported the fourth quarter of 2023 results: revenue $159.2 million, net income $10.9 million, EPS $0.36.

“for the fourth quarter and the audited results for the fiscal year ended December 31, 2023. Fourth Quarter 2023 Highlights ● Net sales increased by 23.6% year-over-year to $159.2 million ● Gross profit increased by 38.8% to $34.7 million from $25.0 million. Gross margin increased to 21.8% from 19.4% in the fourth quarter of 2022 ● Operating income was $13.6”

INTELLINETICS, INC. reported fiscal year ended December 31, 2023 results: revenue $16,886,381, net income $519,266, EPS $0.13 per basic and $0.11 per fully diluted share. Guidance reaffirmed.

“4,017,409 Software maintenance services 1,407,064 1,387,885 Professional services 9,167,428 7,357,937 Storage and retrieval services 1,078,414 1,094,613 Total revenues $ 16,886,381 $ 14,016,928 James F. DeSocio , President & CEO of Intellinetics, stated, “This was a milestone year for Intellinetics, as we expanded our base of recurring SaaS revenue, making”

MANNATECH INC reported the year ended December 31, 2023 results: revenue $132.0 million.

“Total Year 2023 Highlights • Net sales for the year ended December 31, 2023 was $132.0 million, as compared to $137.2 million for the year ended December 31, 2022. Net sales decreased $5.2 million, or 3.8%, for 2023, as compared to 2022. Our 2023 net sales were unfavorably affected by $2.3 million due to the effect of foreign exchange rates. Excluding this impact, Net Sales on a Constant dollar basis (see”

MANNATECH INC reported the fourth quarter ended December 31, 2023 results: revenue $32.7 million, net income $1.8 million, EPS $0.94 per diluted share.

“Fourth quarter 2023 net sales were $32.7 million, a decrease of $1.6 million, or 4.7%, as compared to $34.3 million in the fourth quarter of 2022. • Gross profit as a percentage of net sales improved to 75.4% as compared to 69.0% for the same period in 2022. Reduced supply chain shipping costs more than offset price increases in certain raw materials. • Operating loss in the fourth quarter was $0.9 million, improved from an operating loss of $2.7 million in the fourth quarter of 2022. • Net loss was $1.8 million, or $0.94 per diluted share, for the fourth quarter 2023, as compared to net loss of $6.5 million, or $3.50 per diluted share, for the fourth quarter 2022.”

MSC INDUSTRIAL DIRECT CO INC reported fiscal 2024 second quarter ended March 2, 2024 results: revenue $935.3 million, net income $61.8 million, EPS $1.10. Guidance reaffirmed.

“Net sales of $935.3 million decreased 2.7% YoY”

Jefferies Financial Group Inc. reported quarter ended February 29, 2024 results: revenue $1.74 billion, net income $150 million, EPS $0.66 per diluted common share.

“1 of 9.8%. Adjusting for the impact of the loss on Weiss, our annualized return on adjusted tangible total equity from continuing operations was 12.0% 1 • Net revenues of $1.74 billion Ø Investment Banking net revenues of $740 million Ø Capital Markets net revenues of $712 million, our third best Capital Markets quarter ever Ø Asset Management net revenues”

BioCardia, Inc. reported financial results for the year ended December 31, 2023.

“On March 27, 2024, BioCardia, Inc. issued a press release announcing its financial results for the year ended December 31, 2023.”

FRANKLIN COVEY CO reported second quarter of fiscal 2024 results: revenue $61.3 million, net income $0.9 million, EPS $0.06 per diluted share. Guidance lowered.

“Salt Lake City, Utah 84119-2331 www.franklincovey.com  FRANKLIN COVEY REPORTS SECOND QUARTER FISCAL 2024 FINANCIAL RESULTS  Second Quarter Consolidated Revenue Totals $61.3 Million Compared with $61.8 Million in the Prior Year  Second Quarter Subscription and Subscription Services Sales Total $50.3 Million and a Record $227.3 Million for the Rolling Four”

LANDS' END, INC. reported financial results for its fourth quarter and fiscal year ended February 2, 2024.

“On March 27, 2024, Lands’ End, Inc. (the “Company”) announced its financial results for its fourth quarter and fiscal year ended February 2, 2024. A copy of the Company’s press release containing this information is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.”

CINTAS CORP reported fiscal year 2024 results: revenue annual revenue expectations from a range of $9.48 billion to $9.56 billion to a range of $9.57 billion to $9.60 billion, EPS diluted EPS from a range of $14.35 to $14.65 to a range of $14.80 to $15.00. Guidance raised.

“We are raising our annual revenue expectations from a range of $9.48 billion to $9.56 billion to a range of $9.57 billion to $9.60 billion and our diluted EPS from a range of $14.35 to $14.65 to a range of $14.80 to $15.00.”

CINTAS CORP reported third quarter ended February 29, 2024 results: revenue Revenue for the third quarter of fiscal 2024 was $2.41 billion, net income Net income was $397.6 million, EPS diluted earnings per share (EPS) was $3.84. Guidance raised.

“Revenue for the third quarter of fiscal 2024 was $2.41 billion compared to $2.19 billion in last year’s third quarter, an increase of 9.9%.”

UNIFIRST CORP reported fiscal 2024 results: revenue between $2.415 billion and $2.425 billion, EPS between $6.80 and $7.16. Guidance reaffirmed.

“At this time, we continue to expect our revenues for fiscal 2024 to be between $2.415 billion and $2.425 billion and fully diluted earnings per share to be between $6.80 and $7.16.”

UNIFIRST CORP reported second quarter of fiscal 2024 ended February 24, 2024 results: EPS $1.09.

“Consolidated revenues for the second quarter increased 8.8% to $590.7 million.”

MILLERKNOLL, INC. reported third quarter of fiscal year 2024, which ended March 2, 2024 results: revenue $872.3 million, EPS $0.30 per diluted share.

“MillerKnoll, Inc. Reports Third Quarter Fiscal 2024 Results”